Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant

Inclusion Criteria: * Adult kidney transplant recipient (age ≥18 years at time of transplant) * Kidney-only transplant recipient * Positive EBV serostatus a) EBV serostatus negative or unknown included per the investigator discretion * Received first dose of Nulojix (Belatacept) within ≤ 14 days of renal transplant * Received first dose of Nulojix (Belatacept) as part of normal clinical care (i.e. not as part of a clinical trial) Exclusion Criteria: * Received Nulojix (belatacept) for non kidney transplants * \<18 years of age at time of transplant * Received first dose of Nulojix (belatacept) as an assigned study drug under a clinical trial protocol * EBV-serostatus negative or unknown patients, except by investigator decision * Patient who did not receive Belatacept for de novo treatment * Recipient of concurrent or extant non-kidney organ transplant * Received first dose of Nulojix (belatacept) \> 14 days after date of renal transplant